Nicorette quick - nicotine and mint spray - stop smoking aid 13.2ml

Product Description

Nicorette QuickMist Spray

Nicorette Mist is used for the treatment of tobacco dependence in adults by relieving nicotine withdrawal symptoms, including cravings during a smoking cessation attempt. The ultimate goal is permanent cessation of tobacco use. Use of Nicorette Mist should preferably be combined with a behavioral support program.

Excipients: No clinically significant interactions between nicotine replacement therapy and other medications have yet been confirmed. However, nicotine may enhance the haemodynamic effects of adenosine, i.e., increases in blood pressure and heart rate, as well as pulmonary arterial hypertension. Increased pain response (angina-like chest pain) caused by the administration of adenosine.

Composition: One actuation delivers 1 mg of nicotine in 0.07 ml of solution. 1 ml of solution contains 13.6 mg of nicotine. Excipients with known effect: ethanol (less than 100 mg of ethanol per actuation).

Contraindications: Hypersensitivity to nicotine or to any of the excipients. Children under 18 years of age. Subjects who have never smoked.

Dosage

Subjects must stop smoking completely during treatment with Nicorettemist. Adults and the elderly: The following chart illustrates the recommended timing of use for the oromucosal spray during full treatment (phase I) and in the reduction phases (phase II and phase III). You may use up to 4 sprays per hour. Do not exceed 2 sprays of each dosage and 64 sprays (4 sprays per hour over a 16-hour period) in any 24-hour period. Phase I: Weeks 1 to 6: Use 1 or 2 sprays when you would have smoked a cigarette or if you experience a craving. If a single spray does not control the craving within a few minutes, use a second spray. If 2 sprays are needed, you may use 2 consecutive sprays in the future. Most smokers will need 1 or 2 sprays every 30 minutes to 1 hour. Phase II: Weeks 7 to 9: Begin reducing the number of sprays per day. By the end of Week 9, subjects should have HALVED the average number of daily sprays used in Phase I. Phase III: Weeks 10 to 12 Continue to reduce the number of daily sprays so that, by Week 12, subjects are using no more than 4 sprays per day. Once subjects have reduced the number of sprays to 2–4 per day, use of the oromucosal spray should be discontinued. Example: If you smoke an average of 15 cigarettes per day, 1–2 sprays should be used at least 15 times throughout the day. To aid in continuing smoking cessation after Phase III, subjects may continue to use the oromucosal spray in situations where they are strongly tempted to smoke. A single spray may be used in situations where there is an urge to smoke, with a second spray if the first has not worked within minutes. During this phase, no more than four sprays per day should be used. Regular use of the oromucosal spray for more than 6 months is generally not recommended. Some former smokers may require longer treatment with the oromucosal spray to avoid returning to smoking. Any remaining oromucosal spray should be saved for use in case of a sudden craving. Children and adolescents: Do not administer Nicorettemist to individuals under 18 years of age. There is no experience in treating adolescents under 18 years of age with Nicorettemist. Method of administration: After preparation, point the spray nozzle as close to the mouth as possible. Press the top of the dispenser and release one spray into the mouth, avoiding the lips. Patients should not inhale during actuation to avoid spraying into the airways. For best results, do not swallow for a few seconds after actuation. Patients should not eat or drink at the same time as taking the oromucosal spray. Support and behavioral therapy generally increase the success rate.

Warnings

Nicorettemist should not be used by non-smokers. Dependent smokers who have recently had a myocardial infarction, unstable or worsening angina, including Prinzmetal's angina, serious cardiac arrhythmias, uncontrolled hypertension, or a recent cerebrovascular accident should be encouraged to quit smoking through non-pharmacological interventions (e.g., counseling). If these are unsuccessful, the oromucosal spray may be considered, but as safety data in this patient group are limited, treatment should only be initiated under close medical supervision. Diabetes mellitus. Patients with diabetes mellitus should be advised to monitor their blood glucose levels more closely than usual when stopping smoking and starting NRT, as the nicotine-induced reduction in catecholamine release may increase the risk of heart failure. Affect carbohydrate metabolism. Allergic reactions: predisposition to angioedema and urticaria. A risk-benefit assessment by a competent physician is required for patients with the following conditions: - renal and hepatic impairment: use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment, as decreased clearance of nicotine or its metabolites may occur, with the potential for increased adverse effects; - pheochromocytoma and uncontrolled hyperthyroidism: use with caution in uncontrolled hyperthyroidism or pheochromocytoma, as nicotine causes the release of catecholamines; - gastrointestinal disease: nicotine may exacerbate symptoms in patients with esophagitis, gastric ulcers, or peptic ulcers; NRT preparations should be used with caution in these conditions. Danger in young children: Doses of nicotine tolerated by adult and adolescent smokers can cause serious toxicity in young children, including fatal outcomes. Nicotine-containing products should not be left where they can be misused, handled, or ingested by children; see section 4.9 Overdose. Transmitted dependence: Transmitted dependence can occur, but is less harmful and easier to break than smoking dependence. Smoking cessation: Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs metabolized by CYP1A2 (and possibly CYP1A1). When a smoker stops smoking, they may experience a slower metabolism, resulting in increased blood levels of these drugs. This is potentially more clinically relevant for products with a narrow therapeutic window, such as theophylline, tacrine, clozapine, and ropinirole. With cessation of tobacco use, the plasma concentrations of other medicinal products metabolized in part by CYP1A2 (e.g., imipramine, olanzapine, clomipramine, and fluvoxamine) may increase, although data to support this theory are limited and the possible clinical significance of this effect for these medicinal products is unknown. Limited data indicate that smoking may induce the metabolism of flecainide and pentazocine. Excipients: The oromucosal spray contains small amounts of ethanol (alcohol), less than 100 mg per spray. Care should be taken to avoid contact of the oromucosal spray with the eyes during administration.

Interactions

No clinically significant interactions between nicotine replacement therapy and other medicinal products have yet been confirmed. However, nicotine may induce the metabolism of flecainide and pentazocine. increase the hemodynamic effects of adenosine, namely increased blood pressure and heart rate, as well as increased pain response (angina-like chest pain) caused by adenosine administration.